Navigation Links
Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

annual relapse rate prior to entry, versus patients who received the 20 mg dose (62 percent reduction). The time to the first relapse was significantly delayed from 80 days in the 20 mg group to 213 days in the 40 mg group (p = 0.0367). The overall safety profile was similar to that of the 20 mg dose. Some features of injection site reactions and immediate post-injection reactions were more common.

About Multiple Sclerosis

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over two million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About COPAXONE(R)

COPAXONE(R) is indicated for the reduction of the frequency of relapses in RRMS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, a lump or an indentation at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 phar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Corporation (NYSE: SYK ) reported operating results for ... Third Quarter Highlights Net sales ... to $1,768 million Orthopaedic Implants sales increased 1.3% on ... Equipment sales increased 16.3% on a constant currency basis (16.1% ...
... Calif., Oct. 19 ThermoGenesis Corp. (Nasdaq: ... services that process and store adult stem cells, said ... agreement for its Res-Q™ 60 BMC (Res-Q) System with ... point-of-care cardiovascular therapies. Under the agreement, ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 2ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 3
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Kabi Pty Ltd, one of Australia,s fastest growing and ... (Robotic IV Automation) - a self-contained unit for filling ... (IH Systems) to consolidate its IV preparation. Pharmatel Fresenius ... in June 2009. , The RIVA System and Pharmatel ...
... Feb. 11 Naturs Design, Inc., a privately held ... the revolutionary product that virtually eliminates all of the ... for sleep apnea. Unfortunately, CPAP therapy hasn,t always been ... reports that "many CPAP users never continue therapy beyond ...
... Gynecologic Oncologists, 40th Annual Meeting on Women,s Cancer Proves ... Pa., Feb. 11 New data presented on Saturday ... Oncologists, 40th Annual Meeting on Women,s Cancer demonstrated the ... CA125 blood test results and the Risk of Ovarian ...
... 11 Rising Medical Solutions, Inc. (Rising), ... management organization, announced today that it has ... Accreditation from URAC, a Washington, DC-based health ... quality standards for the health care industry.(Logo: ...
... announced today that Laurence Debroux is ... (CSO).In light of the implementation of the Group,s ... the position of Chief Strategic Officer at the ... business development and acquisition activities as well as ...
... Feb. 11 The Quantum Group, Inc. ( NYSE ... that Pete Martinez, Senior Vice President and Chief Technology ... the St. Thomas University Healthcare Seminar later ... Economic Times." Martinez will contribute to the event ...
Cached Medicine News:Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 3Health News:Rising Medical Solutions Receives URAC Workers' Compensation Utilization Management Accreditation 2Health News:Rising Medical Solutions Receives URAC Workers' Compensation Utilization Management Accreditation 3Health News:Laurence Debroux Appointed Chief Strategic Officer (CSO) 2Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 2Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 3Health News:Quantum Executive Pete Martinez Invited to Participate in University Health Seminar 4
For children up to 4 years of age 11 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... capture and management system that acquires extremely ... Angiography images. It interfaces with most current ... from any ophthalmic device with video, digital ... the features of EyeCap RI, with further ...
The Haag-Streit 81 D lens is a powerful tool for biomicroscopy as well as laser treatment of the fundus. Due to its asymmetric configuration it provides better observation parameters combined with im...
... mirrored surfaces, which each incline at an ... have been cut into the 17 mm ... to examine the opposite iridocorneal angle without ... form of the angle of the iris ...
Medicine Products: